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ABSTRACT
Severe hepatic inﬂammation is a common cause of acute or chronic liver disease. Macrophages are one of
the key mediators which regulate the progress of hepatic inﬂammation. Increasing evidence shows that
the TAM (TYRO3, AXL and MERTK) family of RTKs (receptor tyrosine kinases), which is expressed in
macrophages, alleviates inﬂammatory responses through a negative feedback loop. However, the
functional contribution of each TAM family member to the progression of hepatic inﬂammation remains
elusive. In this study, we explore the role of individual TAM family proteins during autophagy induction
and evaluate their contribution to hepatic inﬂammation. Among the TAM family of RTKs, AXL (AXL
receptor tyrosine kinase) only induces autophagy in macrophages after interaction with its ligand, GAS6
(growth arrest speciﬁc 6). Based on our results, autophosphorylation of 2 tyrosine residues (Tyr815 and
Tyr860) in the cytoplasmic domain of AXL in mice is required for autophagy induction and AXL-mediated
autophagy induction is dependent on MAPK (mitogen-activated protein kinase)14 activity. Furthermore,
induction of AXL-mediated autophagy prevents CASP1 (caspase 1)-dependent IL1B (interleukin 1, b) and
IL18 (interleukin 18) maturation by inhibiting NLRP3 (NLR family, pyrin domain containing 3)
inﬂammasome activation. In agreement with these observations, axl¡/¡ mice show more severe
symptoms than do wild-type (AxlC/C) mice following acute hepatic injury induced by administration of
lipopolysaccharide (LPS) or carbon tetrachloride (CCl4). Hence, GAS6-AXL signaling-mediated autophagy








Liver disease is often initiated by severe hepatic inﬂammation
which mediates progressive liver damage and ﬁbrosis.1,2 During
hepatic inﬂammation, macrophages act as sentinels which initi-
ate immune responses and provide important mediators for
wound healing and metabolic functions.3,4 Therefore, regulat-
ing the activity of macrophages provides an excellent therapeu-
tic strategy to alleviate severe hepatic inﬂammation.
The TAM family of RTKs expressed in macrophages nega-
tively regulates inﬂammatory responses by not only facilitating
the clearance of apoptotic bodies,5,6 but also by providing sig-
nals which inhibit inﬂammation.7,8 Indeed, TAM-deﬁcient
(tyro3¡/¡, axl¡/¡, mertk¡/¡) mice or Mertk mutant mice
develop spontaneous lymphoproliferative diseases such as the
autoimmune disease lupus.9,10
Previous observations show that the interaction between the
TAM family of RTKs and their common ligand, GAS6, plays a
protective role during liver inﬂammation. In a murine ischemia
and reperfusion injury model, Gas6-deﬁcient (gas6¡/¡) mice
show more severe hepatic injury than do wild-type (Gas6C/C)
mice, and treatment of gas6¡/¡mice with exogenous GAS6 res-
cues the phenotype.11 In a murine model of CCl4-induced liver
injury, Gas6 deﬁciency delays wound healing.12 Since GAS6 is a
common ligand of all TAM RTKs, the speciﬁc role of each
TAM family member in the progress of hepatic inﬂammation
remains to be determined.
Autophagy is a homeostatic degradative process that
removes damaged organelles or turns over cytoplasmic constit-
uents via lysosomal compartments in eukaryotic cells.13
Although autophagy was initially identiﬁed to enhance cell
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survival, increasing evidence shows that autophagy is involved
in a variety of biological events.14,15 In particular, recent obser-
vations have demonstrated an inverse relationship between
autophagy induction and maturation of NLRP3 inﬂamma-
somes in macrophages.16-18 Therefore, autophagy may regulate
proinﬂammatory cytokine production via inhibiting activation
of the NLRP3 inﬂammasome in macrophages, which in turn
may contribute to the symptoms of speciﬁc inﬂammatory
diseases.19,20
Given the above information, we explored the role of indi-
vidual TAM family members during autophagy induction and
evaluated their roles in hepatic inﬂammation. We found that
the interaction between AXL and GAS6 induced autophagy via
autophosphorylation of 2 tyrosine residues within the cyto-
plasmic domain of AXL in a manner dependent on MAPK14.
Furthermore, GAS6-AXL-mediated autophagy induction
inhibited NLRP3 inﬂammasome activation, which led to
reduced production of IL1B and IL18. In accordance with these
observations, axl¡/¡ mice showed more severe symptoms than
did wild-type (AxlC/C) mice in acute hepatic injury models.
Therefore, GAS6-AXL signaling inhibits inﬂammatory
responses by inducing autophagy.
Results
Interaction between GAS6 and AXL induces autophagy in
macrophages by increasing mRNA transcript levels of
Becn1, Atg5, andMap1lc3b
To determine the effect of TAM receptor signaling on auto-
phagy induction, we ﬁrst analyzed the surface expression of
each TAM receptor on murine macrophages by ﬂow cytometry.
P388D1 cells expressed relatively higher levels of AXL and
lower levels of MERTK but no TYRO3, whereas J774 cells
expressed MERTK only (Fig. S1). Then, we treated P388D1
and J774 cells with GAS6, a high-afﬁnity ligand for all TAM
receptors, for 24 h.9 To observe autophagy induction, we
expressed a tandem fusion of MAP1LC3B (microtubule associ-
ated protein 1 light chain 3 b) protein to acid-insensitive
mCherry together with GFP (mCherry-EGFP-MAP1LC3B) in
these cells, and then performed morphometric analyses using
confocal microscopy to monitor the formation of autophago-
somes and autolysosomes.21 In these analyses, autophagosomes
were observable as yellow puncta (colocalization between
mCherry and GFP) and autolysosomes appeared as red puncta
(mCherry).21 Also, we measured the ratio of MAP1LC3B-I to
MAP1LC3B-II because the conversion of MAP1LC3B-I to
MAP1LC3B-II is correlated with the formation of autophago-
somes.21,22 The number of yellow puncta and red puncta per
cell increased only in GAS6-treated P388D1 cells (Fig. S2A). In
agreement with this observation, GAS6-treated P388D1 cells
showed increased conversion of MAP1LC3B-I to MAP1LC3B-
II relative to untreated cells, whereas GAS6-treated J774 cells
did not (Fig. S2B). This result was conﬁrmed by treating
P388D1 cells with various concentrations of GAS6 for 24 h.
Autophagy was induced in GAS6-treated P388D1 cells in a
dose-dependent manner (Fig. 1A and B).
We further tested whether the degree of autophagy induc-
tion with GAS6 treatment in macrophages is augmented by
treatment with chloroquine (CQ, a lysosomal acidiﬁcation
inhibitor) or serum deprivation.21 The results indicated that
treatment with CQ and GAS6 increased the level of endoge-
nous MAP1LC3B-II in macrophages, relative to treatment
with GAS6 alone or CQ alone (Fig. S2C). However, serum
deprivation along with GAS6 treatment had no additive effect
on autophagy induction, compared with serum depleted cells
(Fig. S2D).
Next, we treated P388D1 cells with neutralizing antibodies
against AXL, MERTK, or TYRO3 during GAS6 incubation. Our
results indicated that blocking GAS6-AXL signaling abolished
autophagy induction in macrophages after GAS6 treatment
(Fig. 1C and Fig. S3). ATG5 (Autophagy related 5), BECN1
(Beclin 1) and MAP1LC3B proteins are essential for induction of
autophagy.23 Therefore, we monitored the corresponding
mRNA transcripts by qRT-PCR after treatment of P388D1 cells
with GAS6. The expression levels of all of these transcripts
increased within 24 h after GAS6 treatment (Fig. 1D).
Autophagy induction via GAS6-AXL signaling was further
conﬁrmed in wild-type (AxlC/C) and axl¡/¡ mice. Surface
expression of AXL was conﬁrmed on AxlC/C macrophages, and
was not present on axl¡/¡ macrophages (Fig. S4). The surface
expression levels of MERTK and TYRO3 were not different
between AxlC/C and axl¡/¡ macrophages (Fig. S4). Upon GAS6
treatment, the conversion of MAP1LC3B-I to MAP1LC3B-II
increased in AxlC/C macrophages, relative to that in untreated
cells (Fig. 1E). However, no changes in the MAP1LC3B-I to
MAP1LC3B-II ratio were observed in axl¡/¡macrophages after
GAS6 treatment (Fig. 1E). Also, we monitored mRNA tran-
scripts of Atg5, Becn1 and Map1lc3b in GAS6-treated macro-
phages. Induction of these genes was observed in AxlC/C
macrophages, but not in axl¡/¡ macrophages following GAS6
treatment (Fig. 1F). Taken together, these results demonstrate
that GAS6-AXL signaling mediates autophagy induction by
increasing the expression of Atg5, Becn1 and Map1lc3b in
macrophages.
Autophosphorylation of 2 tyrosine residues, Tyr815 and
Tyr860, in the cytoplasmic domain of AXL is required for
autophagy induction
We generated a mutant lacking the entire cytoplasmic domain
of AXL (AXLCYD) (Table S2 and Fig. S5A). Wild-type AXL
(WT AXL) or AXLCYD was expressed in J774 cells which lack
endogenous AXL. The expression level of AXLCYD was compa-
rable to that of WT AXL (Fig. S5B). Then, we treated these cells
with GAS6 to test whether the cytoplasmic domain of AXL is
required for autophagy induction. WT Axl transfectants
showed enhanced conversion of MAP1LC3B-I to MAP1LC3B-
II after GAS6 treatment, whereas AxlCYD transfectants did not
(Fig. 2A). To conﬁrm this observation, we monitored mRNA
transcripts of Atg5, Becn1 and Map1lc3b in WT Axl or AxlCYD
transfectants after GAS6 treatment. Expression of these genes
was induced only in GAS6-treated WT Axl transfectants, and
not in GAS6-treated AxlCYD transfectants (Fig. 2B).
Three tyrosine residues (Tyr773, Tyr815, Tyr860) in the
cytoplasmic domain of mouse AXL have been identiﬁed as
potential autophosphorylation sites which mediate signal trans-
duction.24 To determine which tyrosine residue mediates the
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signal for autophagy induction, we made several mutants with
amino acid substitutions (AXLY773F replaces Tyr773 with
Phe773, AXLY815F replaces Tyr815 with Phe815 and AXLY860F
replaces Tyr860 with Phe860) (Table S2 and Fig. S5A). After
verifying the proper cell surface expression of each mutant pro-
tein on J774 cells (Fig. S5B), we compared the extent of auto-
phagy induction of each mutant transfectant with that of the
WT Axl transfectant after GAS6 treatment. The conversion of
MAP1LC3B-I to MAP1LC3B-II in GAS6-treated WT Axl and
AxlY773F (Tyr773 to Phe773) transfectants was increased rela-
tive to that in untreated cells, whereas the conversion of
MAP1LC3B-I to MAP1LC3B-II in AxlY815F (Tyr815 to
Phe815) and AxlY860F (Tyr860 to Phe860) transfectants was not
(Fig. 2C). To conﬁrm this result, we monitored mRNA levels of
Atg5, Becn1 and Map1lc3b in each transfectant after GAS6
treatment. These genes were induced in WT Axl and AxlY773F
transfectants, but not in AxlY815F and AxlY860F transfectants
(Fig. 2D).
To further verify that Tyr815 and Tyr860 residues are
important for autophagy induction via GAS6-AXL signaling,
we also made a double amino acid substitution mutant
(AXLY815F,Y860F replaces Tyr815 and Tyr860 with Phe815 and
Phe860 respectively) (Table S2 and Fig. S5A and B) and tested
whether this mutant is capable of autophagy induction after
Figure 1. Interaction between GAS6 and AXL induces autophagy in macrophages. (A) mCherry-EGFP-MAP1LC3B expressing P388D1 cells were treated with various con-
centrations of GAS6 for 24 h. After treatment, the formation of autophagosomes (yellow puncta) and autolysosomes (red puncta) was analyzed under a confocal micro-
scope (left panel). Scale bar: 10 mm. Quantiﬁcations of autophagosome and autolysosome formation are shown in the right panel. (B) P388D1 cells were treated with
various concentrations of GAS6 for 24 h. After treatment, cell lysates were subjected to immunoblot analyses using anti-MAP1LC3B antibody and anti-ACTB/actin,
b antibody (left panel). The ratios of MAP1LC3B-I to MAP1LC3B-II are shown in the right panel. (C) mCherry-EGFP-MAP1LC3B-expressing P388D1 cells were treated
with various TAM neutralizing antibodies in the presence or absence of GAS6 (100 ng/ml) for 24 h. Then, the formation of autophagosomes and autolysosomes was
analyzed by confocal microscopy (upper panel). Scale bar: 10 mm. Quantiﬁcations of autophagosome and autolysosome formation are shown in the lower panel. Con-
trol antibody, isotype control; anti-AXL, AXL neutralizing antibody; anti-MERTK, MERTK neutralizing antibody; anti-TYRO3, TYRO3 neutralizing antibody; “¡”, no treat-
ment; “C”, treatment. (D) P388D1 cells were treated with GAS6 (100 ng/ml) for the indicated times. After treatment, qRT-PCR was performed using mRNA from each
cell as a template. (E and F) Peritoneal macrophages isolated from AxlC/C and axl¡/¡ mice were treated with GAS6 (100 ng/ml) for the indicated times. After treat-
ment, cell lysates were subjected to immunoblot analyses (E, left panel). The ratios of MAP1LC3B-I to MAP1LC3B-II are shown (E, right panel). Also, qRT-PCR was
performed using mRNA from each cell as a template (F). AxlC/C, AxlC/C peritoneal macrophages; axl¡/¡, axl¡/¡ peritoneal macrophages. All data represent the mean
§ SEM from 3 independent experiments. P < 0.05; P < 0.01.
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GAS6 treatment. The results clearly demonstrated that the con-
version of MAP1LC3B-I to MAP1LC3B-II and the mRNA lev-
els of Atg5, Becn1 and Map1lc3b were not different in the
GAS6-treated AxlY815F,Y860F transfectant than in untreated cells
(Fig. 2C and D).
Blocking the MAPK14 pathway inhibits AXL-mediated
autophagy induction in macrophages
We tested several different kinase inhibitors to identify those
that would block downstream effectors of GAS6-AXL
Figure 2. Two autophosphorylation residues (Tyr815 and Tyr860) within the cytoplasmic domain of AXL are required for autophagy induction through GAS6-AXL signal-
ing. (A and B) Wild-type AXL (WT AXL) and its cytoplasmic domain deletion mutant (AXLCYD) were expressed in J774 cells. Then, the transfected cells were treated with
GAS6 (100 ng/ml) for 24 h. After treatment, cell lysates were subjected to immunoblot analyses using anti-MAP1LC3B antibody and anti-ACTB antibody (A, left panel).
The ratios of MAP1LC3B-I to MAP1LC3B-II are shown (A, right panel). Also, qRT-PCR was performed using mRNA from each cell as a template (B). “¡”, no treatment;
“C”, treatment; Mock, empty vector transfectant. (C and D) Wild-type AXL (WT AXL) and several AXL mutants were expressed in J774 cells. Then, transfected cells were
treated with GAS6 (100 ng/ml) for 24 h. After treatment, cell lysates were subjected to immunoblot analyses (C, left panel). The ratios of MAP1LC3B-I to MAP1LC3B-II are
shown (C, right panel). Also, qRT-PCR was performed using mRNA from each cell as a template (D). AXLY773F, AXL mutant with Tyr773 to Phe773; AXLY815F, AXL mutant
with Tyr815 to Phe815; AXLY860F, AXL mutant with Tyr860 to Phe860; and AXLY815F,Y860F, AXL double mutant with Tyr815 and Tyr860 to Phe815 and Phe860 respectively.
“¡”, no treatment; “C”, treatment. All data represent the mean § SEM from 3 independent experiments. P < 0.05; P < 0.01.
AUTOPHAGY 2329
signaling in order to determine which downstream pathway is
involved in autophagy induction. After treatment of GAS6
with several kinase inhibitors in J774 cells expressing WT Axl,
the extent of autophagy induction was measured by monitor-
ing the conversion from MAP1LC3B-I to MAP1LC3B-II after
GAS6 treatment. In these experiments, we also assessed the
formation of autophagosomes and autolysosomes by detecting
ﬂuorescence puncta in WT Axl expressing mCherry-EGFP-
MAP1LC3B. As expected, no autophagy induction was
observed in cells after treatment with R428 (AXL inhibitor)
and GAS6 (Fig. 3A and B, and Fig. S6). However, treatment
with U0126 (MAP2K1/2 [mitogen-activated protein kinase
kinase 1/2] and MAPK1/3 inhibitor), SP600125 (MAPK8/9/10
inhibitor), BKM120 (PtdIns3K inhibitor) and rapamycin
(MTOR [mechanistic target of rapamycin] inhibitor) had no
effect on autophagy induction through GAS6-AXL signaling
(Fig. 3A and B and Fig. S6). Notably, treatment with
SB203580 (MAPK11/14 inhibitor) abolished GAS6-AXL-
mediated autophagy induction (Fig. 3A and B and Fig. S6). In
support of this result, Atg5, Becn1 and Map1lc3b mRNA levels
were not increased in cells treated with R428 or SB203580
together with GAS6, whereas they were increased in cells
treated with U0126, SP600125, BKM120, or rapamycin along
with GAS6 (Fig. 3C).
Since SB203580 inhibits both MAPK11 and MAPK14
activities,25 we monitored mRNA transcripts of Mapk11 and
Mapk14 in AXL-expressing J774 cells before or after treat-
ment with GAS6. The mRNA transcript of Mapk14 was
observed whereas mRNA transcript of Mapk11 was hardly
detected in AXL-expressing J774 cells by RT-PCR analyses
(Fig. S7A). Further, we analyzed the activation status of
MAPK11 or MAPK14 using an activation-speciﬁc anti-phos-
pho MAPK antibody in AXL-expressing J774 cells after
treatment with GAS6 and SB203580. MAPK14 activation in
AXL-expressing J774 cells was successfully blocked by treat-
ing SB203580 in a dose-dependent manner. However, no
activation form of MAPK11 was detected in AXL-expressing
J774 cells (Fig. S7B).
To conﬁrm these results, we depleted MAPK14 in AXL-
expressing J774 cells using shRNA and monitored mRNA
transcripts of Atg5 and Becn1 after GAS6 treatment. The
levels of MAPK14 expression were signiﬁcantly decreased in
the shMapk14 plasmid transfectant (shMapk14) when com-
pared to levels in the control plasmid transfectant (control)
(Fig. 3D). Moreover, shRNA-mediated knockdown of
MAPK14 clearly abolished the upregulation of Atg5 and
Becn1 mRNA transcripts after GAS6 treatment (Fig. 3D).
Together, these results indicate that GAS6-AXL signaling
mediated autophagy induction is dependent on the activity
of MAPK14.
To rule out the possibility that NFKB (nuclear factor of
kappa light polypeptide gene enhancer in B cells) is involved in
GAS6-AXL-mediated autophagy induction, we also depleted
Rela (v-rel avian reticuloendotheliosis viral oncogene homolog
A), a key subunit of NFKB, in AXL-expressing J774 cells, using
shRNA and measured the expression patterns of Atg5 and
Becn1 after GAS6 treatment. The shRNA-mediated knockdown
of Rela did not change the expression levels of Atg5 and Becn1
mRNA transcripts after GAS6 treatment (Fig. 3E).
Autophagy induction by GAS6-AXL signaling mediates
suppression of IL1B and IL18 production by inhibiting
NLRP3 inﬂammasome activation
To evaluate whether autophagy induction by GAS6-AXL sig-
naling inhibits NLRP3 inﬂammasome activation in murine
macrophages, we pretreated AxlC/C or axl¡/¡ macrophages
with LPS and GAS6, and then treated them with ATP, a well-
characterized NLRP3 stimulator.26,27
After NLRP3 inﬂammasome activation, the levels of Nlrp3,
Pycard (PYD and CARD domain containing), and Casp1mRNA
transcripts were increased in both AxlC/C and axl¡/¡ macro-
phages. No signiﬁcant change in the mRNA levels of these
inﬂammasome components was observed between AxlC/C and
axl¡/¡ macrophages regardless of the presence or absence of
GAS6 (Fig. 4A). Interestingly, GAS6-treated AxlC/C macro-
phages were found to have reduced levels of cleaved CASP1
(p10, the active form of CASP1) compared to untreated AxlC/C
macrophages (Fig. 4B). However, GAS6-treated axl¡/¡ macro-
phages exhibited no change in the active form of CASP1 relative
to untreated axl¡/¡macrophages (Fig. 4B). Consistent with these
results, GAS6-treated AxlC/C macrophages had reduced levels of
the cleaved form of IL1B, which is produced from a precursor
(PRO-IL1B) by activated CASP1, in response to treatment with
LPS and ATP than did untreated AxlC/C macrophages (Fig. 4C).
However, GAS6-treated axl¡/¡ macrophages and untreated
axl¡/¡ macrophages had comparable levels of the cleaved form
of IL1B (Fig. 4C). These ﬁndings were further conﬁrmed by
ELISA results showing decreases in IL1B and IL18 secretion in
GAS6-treated AxlC/C macrophages compared with untreated
AxlC/C macrophages (Fig. 4D). As expected, no signiﬁcant
changes were observed in the secretion of these proinﬂammatory
cytokines in GAS6-treated or untreated axl¡/¡ macrophages
(Fig. 4D). In addition, glibenclamide (NLRP3 inﬂammasome
inhibitor)18 treatment effectively blocked secretion of IL1B and
IL18 from macrophages treated with LPS and ATP (Fig. 4D).
After activation of the NLRP3 inﬂammasome, we measured
mRNA transcripts of Il1b and Il18 by qRT-PCR to determine
whether treatment of macrophages with GAS6 affects the expres-
sion of these genes. The levels of Il1b and Il18mRNA transcripts
in both AxlC/C and axl¡/¡ macrophages were not altered by
treatment with GAS6 (Fig. 4E). To conﬁrm these results, we pre-
treated Atg7ﬂ/ﬂ Lyz2-CreC(Atg7ﬂ/ﬂ CKO) or Atg7ﬂ/ﬂ Lyz2-Cre¡
(Atg7ﬂ/ﬂ CTRL) macrophages28,29 with LPS and GAS6, and then
treated them with ATP. The results demonstrated that Atg7ﬂ/ﬂ
CKO macrophages were defective in conversion of MAP1LC3B-
I to MAP1LC3B-II after GAS6 treatment, whereas increased
endogenous MAP1LC3B-II levels were found in Atg7ﬂ/ﬂ CTRL
macrophages after GAS6 treatment (Fig. S8A). This result indi-
cates that selective deletion of Atg7 in macrophages causes a
defect in autophagy induction after GAS6 treatment. Further-
more, GAS6-treated Atg7ﬂ/ﬂ CKO macrophages had no changes
in the active form of CASP1 and the cleaved form of IL1B rela-
tive to untreated Atg7ﬂ/ﬂ CKO macrophages (Fig. S8B and C). In
contrast to the results from Atg7ﬂ/ﬂ CTRL macrophages, GAS6-
treated Atg7ﬂ/ﬂ CTRL macrophages were found to have reduced
levels of the active form of CASP1 and the cleaved form of
IL1B relative to untreated Atg7ﬂ/ﬂ CTRL macrophages (Fig. S8B
and C). Supporting these results, levels of IL1B and IL18 secreted
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from GAS6-treated Atg7ﬂ/ﬂ CKO macrophages were the same as
those from untreated Atg7ﬂ/ﬂ CKO macrophages, whereas the
extent of IL1B and IL18 secretion from GAS6-treated Atg7ﬂ/ﬂ
CTRL macrophages was signiﬁcantly decreased (Fig. S8D).
Collectively, these data strongly suggest that GAS6-AXL signal-
ing-mediated autophagy induction inhibits the conversion of the
active forms of IL1B and IL18 through NLRP3 inﬂammasome-
mediated activation of CASP1.
Figure 3. Inhibition of the MAPK14 pathway blocks GAS6-AXL signaling-mediated autophagy induction. (A to C) J774 cells expressing WT AXL or WT AXL and mCherry-
EGFP-MAP1LC3B were treated with GAS6 (100 ng/ml) in the absence or presence of various kinase inhibitors for 24 h. After treatment, cell lysates were subjected to
immunoblot analyses using anti-MAP1LC3B antibody and anti-ACTB antibody (A, left panel). The ratios of MAP1LC3B-I to MAP1LC3B-II are shown (A, right panel). Then,
the formation of autophagosomes (yellow puncta) and autolysosomes (red puncta) was analyzed by confocal microscopy (B, left panel). Scale bar: 10 mm. Quantiﬁcations
of autophagosome and autolysosome formation are shown in the right panel (B, right panel). Also, qRT-PCR was performed using mRNA from each cell as a template (C).
R428, AXL inhibitor; U0126, MAP2K1/2 and MAPK1/3 inhibitor; SP600 (SP600125), MAPK8/9/10 inhibitor; SB203 (SB203580), MAPK11/14 inhibitor; BKM (BKM120),
PtdIns3K inhibitor; Rapa (rapamycin), MTOR inhibitor; “¡”, no treatment; “C”, treatment. (D) Control plasmid (Control) and shMap14 plasmid (shMap14) were transfected
into WT AXL-expressing J774 cells. Then, qRT-PCR and immunoblot analyses were performed to measure the level of MAPK14 expression (left panel). After treatment
with GAS6 (100 ng/ml) for 24 h, qRT-PCR was performed to detect Atg5 and Becn1 mRNA transcripts (right panel). “¡”, no treatment; “C”, treatment. (E) Control plasmid
(Control) and shRela plasmid (shRela) were transfected into WT AXL-expressing J774 cells. Then, qRT-PCR and immunoblot analyses were performed to measure the
level of RELA expression (left panel). After treatment with GAS6 (100 ng/ml) for 24 h, qRT-PCR was performed to detect Atg5 and Becn1 mRNA transcripts (right panel).
“¡”, no treatment; “C”, treatment. All data represent the mean § SEM from 3 independent experiments. P < 0.05; P < 0.01.
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Previous observations demonstrated that STAT1 (signal
transducer and activator of transcription 1)-dependent type I
IFN (interferon) signaling suppresses CASP1 dependent IL1B
maturation by repressing NLRP3 inﬂammasome activation.30
To determine whether NLRP3 inﬂammasome inhibition
through GAS6-AXL signaling is dependent on the activity of
type I IFN and STAT1, we blocked type I IFN signaling using
an anti-IFNAR1 (interferon a and b receptor subunit 1) anti-
body (5A3 clone) and measured the degree of NLRP3 inﬂam-
masome activation in AxlC/C and axl¡/¡ macrophages. After
treatment with anti-IFNAR1 antibody, phosphorylation of
STAT1 (p-STAT1) was decreased in a dose-dependent manner
in LPS-activated macrophages (Fig. S9A). Then, we activated
NLRP3 inﬂammasomes in AxlC/C and axl¡/¡ macrophages by
treatment with an anti-IFNAR1 antibody and GAS6. Our
results indicated that treatment with the anti-IFNAR1 antibody
during NLRP3 inﬂammasome activation did not change the
conversion of PRO-IL1B to mature IL1B in GAS6-treated
AxlC/C or axl¡/¡ macrophages (Fig. S9B). Consistent with this
result, the decrease in IL1B secretion is dependent on GAS6-
AXL signaling, but not on type I IFN signaling (Fig. S9C).
GAS6-AXL signaling-mediated autophagy induction in
Kupffer cells ameliorates acute liver injury by inhibition
of NLRP3 inﬂammasome activation
Since recent observations demonstrated that NLRP3 inﬂamma-
some activation in Kupffer cells contributes to severe liver
inﬂammation,31,32 we investigated whether axl¡/¡ mice aggra-
vate the symptom of acute liver inﬂammation induced by LPS
Figure 4. Autophagy induction through GAS6-AXL signaling reduces IL1B and IL18 secretion by inhibiting NLRP3 inﬂammasome-mediated CASP1 activation. (A to D)
Peritoneal macrophages isolated from AxlC/C and axl¡/¡ mice were treated with LPS (100 ng/ml) for 6 h and then stimulated with ATP (5 mM) in the absence or pres-
ence of GAS6 (100 ng/ml) or NLRP3 inﬂammasome inhibitor (Glib, 100 mM). After treatment, qRT-PCR was performed using mRNA from each cell as a template (A).
Also, cell lysates or culture supernatants were subjected to immunoblot analyses using anti-CASP1 antibody (B) and anti-IL1B antibody (C). Anti-ACTB antibody was
used as an internal control for immunoblotting. Then, ELISAs were performed to detect IL1B and IL18 secretions in culture supernatants (D). “¡”, no treatment; “C”,
treatment; AxlC/C, AxlC/C peritoneal macrophages; axl¡/¡, axl¡/¡ peritoneal macrophages; Sup, culture supernatant; Glib, Glibenclamide. (E) Peritoneal macrophages
isolated from AxlC/C mice were treated with LPS (100 ng/ml) for 6 h in the absence or presence of GAS6 (100 ng/ml). After treatment, qRT-PCR was performed using
mRNA from each cell as a template. All data represent the mean § SEM from 3 independent experiments. P < 0.05; P < 0.01.
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or CCl4. Gas6 mRNA levels were increased in liver and spleen
tissues within 12 h after LPS treatment (Fig. S10). Similarly, the
levels of Nlrp3, Pycard and Casp1 mRNA transcripts were sig-
niﬁcantly increased in both AxlC/C and axl¡/¡ Kupffer cells
within 12 h after LPS treatment (Fig. 5A). These results indicate
that LPS treatment leads to the induction of Gas6 and the
activation of NLRP3 inﬂammasomes in Kupffer cells. After
treatment with LPS, the conversion of MAP1LC3B-I to
MAP1LC3B-II in AxlC/C Kupffer cells was signiﬁcantly
increased relative to that in axl¡/¡ Kupffer cells (Fig. 5B). Con-
sequently, LPS-treated AxlC/C Kupffer cells contained the less
active form of CASP1 (p10), whereas LPS-treated axl¡/¡
Figure 5. Axl deﬁciency in mice aggravates hepatic inﬂammation after LPS challenge. AxlC/C and axl¡/¡ mice were injected intraperitoneally with vehicle (saline, Control)
or LPS (2.5 mg/g). Mice were sacriﬁced and analyzed 12 h after treatment. (A) qRT-PCR was performed using mRNA from AxlC/C or axl¡/¡ Kupffer cells (AxlC/C or axl¡/¡)
as templates. (B) Cell lysates from AxlC/C or axl¡/¡ Kupffer cells were subjected to immunoblot analyses using anti-MAP1LC3B antibody and anti-ACTB antibody (left
panel). The ratios of MAP1LC3B-I to MAP1LC3B-II are shown (right panel). (C) Cell lysates from AxlC/C or axl¡/¡ Kupffer cells were subjected to immunoblot analyses using
anti-CASP1 antibody and anti-ACTB antibody. (D) ELISAs were performed to detect serum concentrations of IL1B and IL18 from AxlC/C or axl¡/¡ mice (AxlC/C or axl¡/¡).
(E) Hematoxylin and eosin (H&E) staining of liver sections (upper left) and liver injury scores (upper right) from AxlC/C or axl¡/¡mice are shown in the upper panel. Immu-
nohistochemisty of liver sections with anti-ﬁbrin(ogen) antibody (lower left) and ﬁbrin(ogen) deposition area (lower right) from AxlC/C or axl¡/¡ mice are shown in the
lower panel. Fibrin(ogen) deposition area D stained area/total image area. Scale bar: 100 mm. (F) Immunohistochemistry of liver sections with anti-ACTA2 antibody, anti-
ADGRE1/F4/80 antibody (ADGRE1), anti-MAP1LC3B antibody (MAP1LC3B) and anti-ATG5 antibody (ATG5) from AxlC/C or axl¡/¡ mice. Each staining area D stained area/
total image area. DAPI staining was performed to visualize nuclei. Scale bar: 100 mm. “¡”, vehicle treatment; “C”, LPS treatment. All data represent the mean § SEM
from 3 independent experiments. P < 0.05; P < 0.01.
AUTOPHAGY 2333
kupffer cells did not (Fig. 5C). Consistent with these results,
IL1B and IL18 secretions in sera taken from LPS-treated AxlC/C
mice were signiﬁcantly decreased compared with those in sera
from LPS-treated axl¡/¡ mice (Fig. 5D). However, the levels of
Il1b and Il18 mRNA transcripts in AxlC/C and axl¡/¡ Kupffer
cells were comparable (Fig. S11).
To conﬁrm that NLRP3 inﬂammasome activation is
involved in the increased inﬂammation seen in axl¡/¡ mice, we
used glibenclamide to inhibit NLRP3 inﬂammasome activation
in this animal model.33 The results showed that glibenclamide
treatment diminished the active form of CASP1 (p10) in both
LPS-treated AxlC/C and axl¡/¡ Kupffer cells (Fig. S12A). Also,
glibenclamide treatment caused a signiﬁcant decrease in IL1B
and IL18 levels in sera taken from LPS-treated AxlC/C or axl¡/¡
mice (Fig. S12B).
Liver tissue specimens from AxlC/C and axl¡/¡ mice were
obtained 12 h after LPS treatment. Normal histology was
observed in the control groups without treatment (Fig. 5E, upper
panels). In contrast, marked histological changes (multiple ero-
sions, inﬂammatory cell inﬁltration and bleeding) were observed
in the LPS-treated groups (Fig. 5E, upper panels). More severe
tissue injury was observed in the LPS-treated axl¡/¡ group than
in the AxlC/C group. Accordingly, liver injury score was higher
in specimens from the LPS-treated axl¡/¡ mouse group than in
those from the LPS-treated AxlC/C mouse group (Fig. 5E, upper
panels). Consistent with this, more severe kidney and lung tissue
injury was also observed in LPS-treated axl¡/¡ mice compared
with AxlC/Cmice (Fig. S13).
The degree of ﬁbrin deposition in the liver is a useful indica-
tor of measuring the severity of acute liver injury.34 The
amount of ﬁbrin deposition in LPS-treated axl¡/¡mice was sig-
niﬁcantly greater than in AxlC/Cmice (Fig. 5E, lower panels). In
order to access the severity of liver injury, we also measured
hepatic stellate cell (HSC) activation by staining with anti-
ACTA2 (actin, a 2, smooth muscle, aorta) antibody (green
ﬂuorescence) and visualized the number of macrophages within
the lesions by staining with anti-ADGRE1/F4/80 antibody (red
ﬂuorescence).35 The results showed that activated HSCs and
inﬁltrated macrophages at the sites of injury were more numer-
ous in the livers of LPS-treated axl¡/¡ mice than in those of
AxlC/Cmice (Fig. 5F, upper 2 panels).
The combined results indicate that axl¡/¡ mice show more
severe inﬂammation following LPS-induced liver injury
because axl¡/¡mice cannot inhibit NLRP3 inﬂammasome acti-
vation due to deﬁcits in GAS6-AXL signaling-mediated auto-
phagy induction. Supporting this idea, immunohistochemical
staining with anti-MAP1LC3B antibody and anti-ATG5 anti-
body showed that the number of cells expressing MAP1LC3B
and ATG5 proteins was markedly elevated in liver tissue from
LPS-treated AxlC/C mice compared with that from LPS-treated
axl¡/¡ mice (Fig. 5F, lower 2 panels).36,37 The liver function of
experimental animals was further determined by measuring
serum levels of GPT (glutamic pyruvic transaminase, soluble)
and GOT1 (glutamic-oxaloacetic transaminase 1, soluble).
Serum levels of GPT and GOT1 were more elevated in the LPS-
treated axl¡/¡ group than in the LPS-treated AxlC/C group
(Fig. S14).
Using a more liver-speciﬁc injury model to evaluate the
inhibitory effect of GAS6-AXL signaling on NLRP3
inﬂammasome activation, we performed the same sets of experi-
ments in mice subjected to intraperitoneal injections of either
CCl4 or vehicle. Gas6 mRNA transcript levels increased in liver
tissue of CCl4-treated animals 24 h after treatment (Fig. S15).
Also, Nlrp3, Pycard and Casp1 mRNA levels were elevated in
AxlC/C and axl¡/¡ Kupffer cells 24 h after CCl4 treatment
(Fig. 6A). The conversion of MAP1LC3B-I to MAP1LC3B-II in
AxlC/C Kupffer cells was signiﬁcantly increased relative to that
in axl¡/¡ Kupffer cells following treatment with CCl4 (Fig. 6B).
Consequently, Kupffer cells from CCl4-treated Axl
C/C mice
expressed the less active form of CASP1 (p10), whereas axl¡/¡
Kupffer cells from CCl4-treated mice did not (Fig. 6C). Support-
ing this result, IL1B and IL18 secretions 24 h after CCl4 treat-
ment were signiﬁcantly decreased in sera from AxlC/C mice,
compared with that from axl¡/¡ mice (Fig. 6D). However, the
levels of Il1b and Il18 mRNA transcripts in AxlC/C and axl¡/¡
Kupffer cells were not signiﬁcantly different (Fig. S16).
To investigate whether NLRP3 inﬂammasome activation
participates in the increased inﬂammation observed in axl¡/¡
mice, we used glibenclamide to inhibit the activation of NLRP3
inﬂammasome in this animal model.32 Glibenclamide treat-
ment in both CCl4-treated Axl
C/C and axl¡/¡ Kupffer cells led
to decreased conversion of active CASP1 (p10) (Fig. S17A).
Also, the amounts of IL1B and IL18 in sera taken from CCl4-
`treated AxlC/C and axl¡/¡ mice were signiﬁcantly reduced by
glibenclamide treatment (Fig. S17B).33
Liver tissue specimens from axl¡/¡ and AxlC/C mice were
collected 2 d after CCl4treatment. Specimens from the CCl4-
treated axl¡/¡ group had higher liver injury scores and a higher
degree of ﬁbrin deposition than did those from the CCl4-
treated AxlC/C group (Fig. 6E). In agreement with these obser-
vations, inﬁltration of activated HSCs and ADGRE1-positive
macrophages into injury sites was increased in livers from
CCl4-treated axl
¡/¡ mice than in those of CCl4-treated AxlC/C
mice (Fig. 6F, upper 2 panels). Also, the number of cells
expressing MAP1LC3B and ATG5 proteins was elevated in liv-
ers from CCl4-treated Axl
C/C mice compared with those from
CCl4-treated axl
¡/¡ mice (Fig. 6F, lower 2 panels), and serum
levels of GPT and GOT1 on d 2 post-CCl4 treatment were sta-
tistically higher in CCl4-treated axl
¡/¡ mice than in CCl4-
treated AxlC/Cmice (Fig. S18). These combined results are con-
sistent with the result from the LPS-induced liver injury model
and demonstrate that GAS6-AXL signaling inhibits NLRP3
inﬂammasome activation through autophagy induction follow-
ing CCl4-induced liver injury.
Discussion
This study provides novel evidence showing that GAS6-AXL
signaling promotes autophagy induction in murine macro-
phages, which may depress acute liver inﬂammation by inhib-
iting NLRP3 inﬂammasome activation. Based on our study,
AXL is the only molecule that induces autophagy among
TAM receptors. This result was further conﬁrmed by the
observation that mRNA expression levels of Atg5, Becn1 and
Map1lc3b, essential genes for autophagy induction,23 increased
when we triggered GAS6-AXL signaling. Consistent with this
observation, autophagy induction via GAS6-AXL signaling
was found to be defective in axl¡/¡ macrophages.
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We also provide molecular evidence showing that the cyto-
plasmic domain of AXL is critical for autophagy induction.
Our experiments with several AXL mutants revealed that 2
autophosphorylated tyrosine residues (Tyr815 and Tyr860) in
the cytoplasmic domain of AXL are required for autophagy
induction. Our next question addressed which downstream sig-
naling molecule mediates autophagy induction through GAS6-
AXL signaling. GAS6-AXL signaling has been linked to
Figure 6. Axl-deﬁcient mice display more severe hepatic inﬂammation after CCl4treatment. Axl
C/C and axl¡/¡ mice were injected intraperitoneally with vehicle (corn oil,
Control) or CCl4 (2 ml/g). Mice were sacriﬁced and analyzed 2 d after treatment. (A) qRT-PCR was performed using mRNA from Axl
C/C or axl¡/¡ Kupffer cells (AxlC/C or
axl¡/¡) as templates. (B) Cell lysates from AxlC/C or axl¡/¡ Kupffer cells were subjected to immunoblot analyses using anti-MAP1LC3B antibody and anti-ACTB antibody
(left panel). The ratios of MAP1LC3B-I to MAP1LC3B-II are shown (right panel). (C) Cell lysates from AxlC/C or axl¡/¡ Kupffer cells were subjected to immunoblot analyses
using anti-CASP1 antibody and anti-ACTB antibody. (D) ELISAs were performed to detect serum concentrations of IL1B and IL18 from AxlC/C or axl¡/¡ mice (AxlC/C or
axl¡/¡). (E) Hematoxylin and eosin (H&E) staining of liver sections (upper left) and liver injury scores (upper right) from AxlC/C or axl¡/¡mice are shown in the upper panel.
Immunohistochemisty of liver sections with anti-ﬁbrin(ogen) antibody (lower left) and ﬁbrin(ogen) deposition area (lower right) from AxlC/C or axl¡/¡ mice are shown in
the lower panel. Fibrin(ogen) deposition area D stained area/total image area. Scale bar: 100 mm. (F) Immunohistochemistry of liver sections with anti-ACTA2 antibody,
anti- ADGRE1/F4/80 antibody (ADGRE1), anti-MAP1LC3B antibody (MAP1LC3B) and anti-ATG5 antibody (ATG5) from AxlC/C or axl¡/¡ mice. Each staining area D stained
area/total image area. DAPI staining was performed to visualize nuclei. Scale bar: 100 mm. “¡”, vehicle treatment; “C”, CCl4 treatment. All data represent the mean§ SEM
from 3 independent experiments. P< 0.05; P< 0.01.
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multiple downstream pathways through GRB2 and PtdIns3K.38
Previously identiﬁed downstream effector molecules of GRB2
and PtdIns3K that transmit GAS6-AXL signaling include
MAPK14, MAP2K1/2, MAPK1/3, and MAPK8/9/10, which
promote cell migration, proliferation, and survival of different
cell types.38 GAS6-AXL signaling also mediates activation of
NFKB through PtdIns3K.38,39 We found that treatment with
the MAPK11/14 inhibitor alone was sufﬁcient to block GAS6-
AXL signaling-mediated autophagy induction. This observa-
tion was further conﬁrmed by the result that inhibition of
MAPK14 activity mediated throgh shRNA abolished GAS6-
AXL signaling-mediated autophagy induction.
The NLRP3 inﬂammasome in macrophages is a protein
complex which consists of NLRP3, PYCARD, and CASP1.40,41
After recognition of several pathogen-associated molecular pat-
terns, NLRP3 inﬂammasomes control the maturation and
secretion of IL1B and IL18 by activating CASP1.40,41 Nlrp3,
Pycard or Casp1 deﬁcient mice show signiﬁcant defects in
secretion of IL1B and IL18 after treatment with LPS and
ATP.26,27 Recently, an inverse relationship between autophagy
induction and NLRP3 inﬂammasome activation has been pro-
posed.16-18 Indeed, mice lacking genes encoding several auto-
phagy proteins such as ATG16L1, BECN1, and MAP1LC3B
produce excessive amounts of IL1B and IL18 in response to
LPS or LPS and ATP.16-18
To clarify the biological relationship between autophagy
induction through GAS6-AXL signaling and NLRP3 inﬂamma-
some activation, we explored the possibility that autophagy
induction through GAS6-AXL signaling may inhibit NLRP3
inﬂammasome activation in macrophages. Our results clearly
indicated that autophagy induction through GAS6-AXL signal-
ing inhibits NLRP3 inﬂammasome-dependent activation of
CASP1. Previous observations show that autophagy inhibits
NLRP3 inﬂammasome activation by reducing the concentra-
tion of reactive oxygen species (ROS).17,18 Supporting this idea,
several observations show that autophagy negatively regulates
ROS generation,16,42 and NLRP3 inﬂammasome activity is sup-
pressed by ROS blockade.41 In agreement with these reports,
we detected less ROS in GAS6-treated AxlC/C macrophages
than in untreated AxlC/C macrophages during NLRP3 inﬂam-
masome activation (Fig. S19A). Also, PYCARD multimer for-
mation was decreased in AxlC/C macrophages treated with
GAS6, but not in axl¡/¡ macrophages (Fig. S19B). Neverthe-
less, most previous observations have used speciﬁc gene-deﬁ-
cient mouse models to speculate on the relationship between
autophagy and NLRP3 inﬂammasome activation.16-18 However,
our results provide direct evidence showing that autophagy for-
mation by GAS6-AXL signaling indeed inhibits NLRP3 inﬂam-
masome activity.
Previously, 2 independent studies have shown that GAS6-
AXL signaling inhibits the secretion of proinﬂammatory cyto-
kines. The ﬁrst study demonstrates that GAS6-AXL signaling
induces the expression of Twist1 (twist family bHLH transcrip-
tion factor 1), which inhibits the NFKB dependent transcription
of Tnf.7 The second study indicates that IFNA receptor-STAT1-
dependent AXL signaling induces Socs1 and Socs3, which
inhibit toll-like receptor and cytokine receptor signaling.8 Our
results showed that autophagy induced by GAS6-AXL signaling
is NFKB-independent and that mRNA levels of Il1b and Il18 do
not change after treatment with GAS6. Also, we showed that
the inhibition of NLRP3 inﬂammasome activation via GAS6-
AXL signaling is independent of IFNA-STAT1 signaling.
Therefore, the proposed mechanism herein by which GAS6-
AXL signaling inhibits proinﬂammatory cytokine secretion is
different from those proposed in the other studies mentioned
above.7,8 Our results demonstrate a novel mechanism of GAS6-
AXL signaling which blocks proinﬂammatory cytokine produc-
tion by inhibiting NLRP3 inﬂammasome mediated CASP1 acti-
vation through autophagy induction. Therefore, 2 previous
observations together with our results, strongly suggest that
GAS6-AXL signaling is important in regulation of the inﬂam-
matory response using different effector molecules such as
TWIST1, SOCS1, SOCS3 or MAPK14.7,8
Increasing evidence demonstrates the importance of
NLRP3 inﬂammasome regulation in Kupffer cells during liver
inﬂammation. For example, NLRP3 inﬂammasome activation
in Kupffer cells often causes severe liver inﬂammation.31,32
Also, a recent study reports spontaneous generation of severe
liver inﬂammation in myeloid cell-speciﬁc hyperactive Nlrp3
transgenic mice.43 In the current study, we demonstrated the
physiological relevance of GAS6-AXL signaling-mediated
autophagy induction on NLRP3 inﬂammasome-medicated
CASP1 activation in LPS- or CCl4-induced acute liver injury
models. First, we demonstrated that GAS6 secretion and
NLRP3 inﬂammasome activation in Kupffer cells are induced
by LPS or CCl4 treatment in mice. Second, we showed that
autophagy induction and NLRP3 inﬂammasome-mediated
CASP1 activation are inversely correlated. Third, axl¡/¡ mice
were more susceptible to LPS- or CCl4-induced acute liver
injury and showed enhanced expression of IL1B and IL18.
The combined results suggest that deﬁcits in GAS6-AXL sig-
naling in axl¡/¡ Kupffer cells result in insufﬁcient inhibition
of NLRP3 inﬂammasome activation and thus lead to more
severe liver inﬂammation.
Based on our results, we propose a novel role for GAS6-AXL
signaling during acute liver injury. During the early stages of
liver injury induced by LPS or CCl4treatment, CASP1 is acti-
vated through the NLRP3 inﬂammasome in Kupffer cells and
proinﬂammatory cytokines such as IL1B and IL18 are promptly
secreted by kupffer cells (Fig. 7). At the same time GAS6 levels
are substantially increased and the interaction between GAS6
and AXL leads to autophagy induction in Kupffer cells (Fig. 7).
Then, the autophagy prevents further activation of CASP1
through inhibition of NLRP3 inﬂammasome activation in
kupffer cells (Fig. 7).
Although the effect of GAS6-AXL signaling in the liver
seems to be antiinﬂammatory in conditions of acute inﬂamma-
tion, 2 previous observations have found that TAM signaling
promotes liver ﬁbrosis during chronic inﬂammation. The ﬁrst
study demonstrates that Gas6 deﬁciency attenuates hepatic
steatosis by reducing macrophage inﬁltration and attenuating
hepatic progenitor cell activation.44 The second study indicates
that GAS6-AXL signaling promotes liver ﬁbrogenesis by
hepatic stellate cell activation.45 These results, along with ours,
may reﬂect differential effects of TAM signaling that are depen-
dent on particular downstream molecules in different target
cells since multiple and divergent downstream effectors are
involved in GAS6-AXL signaling.38
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In conclusion, this study shows that the GAS6-AXL signal-
ing pathway mediates autophagy induction in macrophages
through MAPK14, and that this effect depends on the Tyr815
and Tyr860 residues in the cytoplasmic domain of AXL. Fur-
thermore, we show that GAS6-AXL signaling-mediated auto-
phagy induction in Kupffer cells prevents more severe
inﬂammation by inhibiting NLRP3 inﬂammasome activation
in murine acute liver injury models induced by LPS or CCl4.
These ﬁndings provide the ﬁrst evidence that AXL signaling
regulates autophagy in macrophages, and that autophagic activ-
ity in Kupffer cells is a key factor that determines the extent of
secretion of proinﬂammatory cytokines such as IL1B and IL18
during acute liver injury.
Materials and methods
Antibodies and reagents
The antibodies used are the following: anti-MAP1LC3B antibody
(Cell Signaling Technology, 2775), anti-MAPK11 antibody (Cell
Signaling Technology, 2339), anti-MAPK14 antibody (Cell Sig-
naling Technology, 9218), anti-phosphorylated MAPK antibody
(Cell Signaling Technology, 9216), anti-ATG5 antibody (Cell
Signaling Technology, 8540), anti-phosphorylated STAT1 anti-
body (Cell Signaling Technology, 9167), anti-ACTB/actin, b
antibody (Sigma, A5441) and anti-ACTA2 antibody (mouse
IgG2a; Sigma, A2547), anti-mouse AXL antibody (rat IgG2a;
R&D systems, MAB8541), rat IgG2a isotype control (R&D sys-
tems, MAB006), anti-mouse MERTK antibody (rat IgG1; R&D
systems, MAB591), rat IgG1 isotype control (R&D systems,
MAB005), biotinylated anti-mouse TYRO3 antibody (rat IgG1;
R&D systems, BAM759), rat IgG1 biotinylated isotype control
(R&D systems, IC005B), anti-mouse AXL neutralizing antibody
(goat polyclonal; R&D systems, AF854), anti-mouse MERTK
neutralizing antibody (goat polyclonal; R&D systems, AF591),
anti-mouse TYRO3 neutralizing antibody (goat polyclonal; R&D
systems, AF759), goat IgG antibody isotype control (R&D sys-
tems, AB-108-C), FITC-conjugated anti-ITGAM/CD11b anti-
body (rat IgG2b; eBioscience, 11-0112), FITC-conjugated rat
IgG2b isotype control (eBioscience, 11-4031), anti-mouse AXL
antibody (Santa Cruz Biotechnology, sc-20741), anti-IL18 anti-
body (Santa Cruz Biotechnology, sc-7954), anti-RELA antibody
(Santa Cruz Biotechnology, sc-372), anti-STAT1 antibody (Santa
Cruz Biotechnology, sc-346), anti-CASP1 antibody (Santa Cruz
Biotechnology, sc-514), anti-PYCARD antibody (Santa Cruz
Biotechnology, sc-22514-R), goat anti-mouse IgG-HRP (Santa
Cruz Biotechnology, sc-2005), goat anti-rabbit IgG-HRP (Santa
Cruz Biotechnology, sc-2004), anti-ADGRE1/F4/80 antibody
(rat IgG2a; Thermo Fisher Scientiﬁc, MF48000), Alexa Fluor 488-
conjugated anti-mouse IgG (Thermo Fisher Scientiﬁc, A-11001),
Alexa Fluor 488-conjugated anti-rat IgG (Thermo Fisher Scien-
tiﬁc, A-11006), Alexa Fluor 594-conjugated anti-rabbit IgG
(Thermo Fisher Scientiﬁc, A-11037), PE-conjugated anti-
ADGRE1/F4/80 antibody (Thermo Fisher Scientiﬁc, MF48004),
rabbit anti-mouse ﬁbrin(ogen) antiserum (Molecular Innova-
tions, ASMFBGN), anti-IL1B antibody (BioVision, 5129-100),
anti-mouse IFNA receptor antibody (mouse IgG1; BioXcell,
BE0241), mouse IgG1 isotype control (BioXcell, BE0083),
Figure 7. Schematic summary for the role of GAS6-AXL signaling-mediated autophagy during LPS- or CCl4-mediated acute liver injury. Our results suggest that autophagy
induced by GAS6-AXL signaling represses hepatic inﬂammatory response via a negative feedback loop. During the early stages of liver inﬂammation induced by LPS or
CCl4, Kupffer cells promptly secrete mature IL1B and IL18 through NLRP3 inﬂammasome-mediated activation of CASP1. Simultaneously, GAS6 induced by LPS or CCl4
binds to AXL, which subsequently leads to the induction of autophagy. Then, autophagy inhibits further secretion of mature IL1B and IL18 by blocking NLRP3 inﬂamma-
some activation.
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biotinylated goat anti-rat IgG (Vector Laboratories, BA-9400),
Streptavidin-PE (BD Biosciences, 349023), and anti-PE microbe-
ads (Miltenyi Biotec, 130-048-801). The reagents used are the fol-
lowing: Recombinant mouse GAS6 (R&D systems, 986-GS),
R428 (AXL inhibitor; Selleck Chemicals, S2841), SP600125
(MAPK8/9/10 inhibitor; Sigma, S5567), glibenclamide (NLRP3
inﬂammasome inhibitor; Sigma, G0639), U0126 (MAP2K1/2
and MAPK1/3 inhibitor; InvivoGen, tlrl-u0126), SB203580
(MAPK11/14 inhibitor; InvivoGen, tlrl-sb20), BKM120
(PtdIns3K inhibitor; Selleck Chemicals, S2247), rapamycin (LC
Laboratories, R5000), LPS (Sigma, L4391), CQ (Sigma, C6628),
ATP (Sigma, A2383), CCl4 (Junsei Chemical, 33650-0330), Mito-
SOX Red mitochondrial superoxide indicator (Invitrogen,
M36008).
Cells
Murine macrophage cell lines (P388D1 and J774) were main-
tained in DMEM (Invitrogen, 11965-084) supplemented with
5% fetal bovine serum (Hyclone, SH30071) and 1% penicillin/
streptomycin (Invitrogen, 15140-122). The pBABE-puro
mCherry-EGFP-LC3B plasmid (Addgene, 22418; deposited by
Dr. Jay Debnath). mCherry-EGFP-MAP1LC3B-expressing
P388D1 and J774 cell lines were established as previously
described.46
Peritoneal macrophages were isolated from axl¡/¡, AxlC/C,
Atg7ﬂ/ﬂ Lyz2-CreC (Atg7ﬂ/ﬂ CKO) or Atg7ﬂ/ﬂ Lyz2-Cre¡
(Atg7ﬂ/ﬂ CTRL) mice (8-wk old) as previously described.47
Brieﬂy, mice were intraperitoneally injected with 1 ml of 3%
Brewer thioglycollate (BD Biosciences, 211716). Three d after
injection, cells were isolated by ﬂushing out the peritoneal cav-
ity using 10 ml of phosphate-buffered saline (PBS; 135 mM
NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4, pH
7.4) without calcium and magnesium. Cells were then plated
on culture dishes and incubated at 37C and 5% CO2 in
DMEM/F-12 medium (Invitrogen, 11330-032) supplemented
with 10% (v/v) fetal bovine serum and 1% penicillin/strepto-
mycin for 4 h. Subsequently, nonadherent cells were removed
by gently washing 3 times with warm PBS. Adherent cells
were counted, stained with FITC-conjugated anti-ITGAM/
CD11b antibody, and analyzed using ﬂow cytometry. More
than 90% of cells were ITGAM-positive.
Measurement of autophagy induction
Cells were treated with various concentrations of recombinant
GAS6, CQ and/or serum deprivation for 24 h. Also, various
combinations of neutralizing antibodies including anti-mouse
AXL antibody (2 mg/ml), anti-mouse MERTK antibody (2 mg/
ml), and anti-mouse TYRO3 antibody (2 mg/ml), or inhibitors
including R428 (AXL inhibitor, 2.5 mM), SP600125 (MAPK8/
9/10 inhibitor, 10 mM), U0126 (MAP2K1/2 and MAPK1/3
inhibitor, 5 mM), SB203580 (MAPK11/14 inhibitor, 2.5 mM),
BKM120 (PtdIns3K inhibitor, 1 mM) and rapamycin (MTOR
inhibitor, 100 nM) were added to block autophagy induction
after GAS6 treatment. After treatment, autophagy induction in
each cell was measured via immunoblotting and confocal
microscopy. Also, Atg5, Becn1 and Map1lc3b mRNA levels
were measured by quantitative reverse-transcriptase polymer-
ase chain reaction (qRT-PCR).
Western blot analyses
Cells were washed 3 times with PBS, centrifuged, and lysed with
RIPA lysis solution (50 mM Tris, pH 7.4, 150 mM NaCl, 1%
NP-40 [Sigma, 74385], 0.5% sodium deoxycholate [Sigma,
D6750], 0.1% SDS [Sigma, L4509]) containing 200 mg/ml of
phenylmethylsulfonyl ﬂuoride (Sigma, P7626), phosphatase
inhibitor cocktail (Sigma, P0044) and protease inhibitor cock-
tail (Millipore, 535140). The cell lysates were subsequently
resolved by 12% SDS-polyacrylamide gel electrophoresis, trans-
ferred onto Immobilon P membranes (Millipore, IPVH00010),
and immunoblotted with appropriate antibodies. Immunoreac-
tive bands were visualized using an ECL solution (GE Health-
care, RPN2232). To determine the MAP1LC3B-I to
MAP1LC3B-II ratio, immunoreactive bands were quantiﬁed
using ImageJ software version 1.43u (National Institutes of
Health, Bethesda, MD, USA). Then, the values of MAP1LC3B-
I to MAP1LC3B-II ratio were relative to the control value of
the experiment. To quantify the relative expression of other
proteins, immunoreactive bands were normalized to ACTB
levels.
Confocal microscopy
To observe autophagy induction, mCherry-EGFP-MAP1LC3B-
expressing P388D1 cells and J774 cells were treated with vari-
ous combinations of recombinant GAS6, neutralizing antibody
and/or inhibitors. The cells were then washed 3 times with PBS
and ﬁxed with 4% paraformaldehyde (Sigma, P6148) in PBS at
room temperature for 10 min. After washing 3 times with PBS,
cells were stained with a mounting solution containing DAPI
(Vector Laboratories, H-1200) and imaged by confocal micros-
copy on an LSM 5 EXCITER (Carl-Zeiss, Oberkochen,
Germany).
qRT-PCR
The mRNA transcripts of mouse Atg5, Becn1, Map1lc3b, Gas6,
Il1b, Il18, Nlrp3, Pyard and Casp1 were quantitatively measured
by real-time PCR analyses. The mRNA transcript of mouse
Gapdh was used as an internal control for qRT-PCR. Brieﬂy,
total RNAs from cells or tissues were isolated using Trizol
reagent according to the manufacturer’s protocol (Thermo
Fisher Scientiﬁc, 15596-026), and reverse transcribed into
cDNA using the First-Strand cDNA Synthesis Kit with oligo-
dT primers and Super-Script RT (Thermo Fisher Scientiﬁc,
K1622). After cDNA synthesis, quantitative real-time PCR was
conducted using a 7500 Real-time PCR system (Applied Bio-
systems, Foster City, CA, USA). The primer pairs used for
qRT-PCR are listed in Table S1.
Cloning and expression of mutant Axl
Several amino acid substitution mutants of Axl were cloned
with PCR from the mouse Axl gene (GenBank accession
BC050914) and expressed in macrophages (J774 cell) via
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retroviral transduction. The cDNA of wild-type mouse Axl was
isolated by RT-PCR using total RNAs of P388D1 as a template.
The expression vectors encoding wild-type mouse Axl (WT
Axl), the cytoplasmic domain deletion mutant of Axl (AxlCYD),
Axl mutants with a single amino acid substitution (AxlY696F,
AxlY697F, AxlY773F, AxlY815F, and AxlY860F), and an Axl mutant
with a double amino acid substitution (AxlY815F,Y860F) were
constructed by cloning PCR products using NotI and SalI
restriction sites in the retroviral vector pLNCX2 (Clontech,
631503). PCR was performed using the cDNA of wild-type
mouse Axl as a template. The primer pairs used for each
expression vector are listed in Table S2. The schematic dia-
grams of individual proteins expressed from DNA constructs
are shown in Supporting Fig. 5A. Each DNA construct was
then transfected into 293GPG cells using Lipofectamine
(Thermo Fisher Scientiﬁc, 11668-019). After 3 d, the superna-
tant from each transfectant was used to infect J774 cells using
1 mg/ml of polybrene (Sigma, H9268). To establish stable cell
lines, each group of infected cells was selected with 1.5 mg/ml
neomycin (Sigma, N1876). Proper cell surface expression of
wild-type AXL and its mutants were observed by ﬂow cytome-
try analyses.
Flow cytometry analyses
Flow cytometry analyses were performed to determine the cell
surface expression of mouse AXL, MERTK, TYRO3 and
ITGAM. For surface staining of AXL or MERTK, cells were
stained with either puriﬁed anti-AXL antibody (rat IgG2a) or
anti-MERTK antibody (rat IgG1), followed by biotinylated goat
anti-rat IgG and streptavidin-PE. Rat IgG2a and rat IgG1 con-
trol were used as isotype controls. For surface staining of
TYRO3, cells were stained with biotinylated anti-mouse
TYRO3 antibody (rat IgG1) in combination with streptavidin-
PE. Biotinylated rat IgG1 was used as an isotype control. To
visualize ITGAM surface expression, cells were stained with
FITC-conjugated anti-ITGAM antibody (rat IgG2b). FITC-con-
jugated rat IgG2b control was used as an isotype control. After
washing several times with PBS, all stained cells were resus-
pended in PBS and analyzed by ﬂow cytometry using a FACS-
Calibur with CellQuest software (BD Biosciences, San Jose, CA,
USA).
RT-PCR
The mRNA transcripts of mouse Mapk11 and Mapk14 were
measured by RT-PCR analyses. The cDNA synthesis was
described as above. After cDNA synthesis, PCR was conducted
using a SimpliAmp Thermal Cycler (Thermo Fisher Scientiﬁc).
The resulting PCR products were loaded onto a 1.5% agarose
gel containing ethidium bromide, and were visualized using
ultraviolet light. The primer pairs used for qRT-PCR are listed
in Table S3.
Co-immunoprecipitation
AXL-expressing J774 cells were washed in PBS and resuspended
in cell lysis buffer (50 mM Tris HCl, pH 7.4, 150 mM NaCl, 1%
NP-40) containing 200 mg/ml of phenylmethylsulfonyl ﬂuoride,
phosphatase inhibitor cocktail and protease inhibitor cocktail.
The lysates were incubated with anti-MAPK11 antibody or
anti-MAPK14 antibody and precipitated with protein G
sepharoseTM Fast Flow (GE Healthcare, 17-0618-01). The pre-
cipitated proteins were resolved via SDS-PAGE, transferred to
Immobilon-P membranes, and immunoblotted with anti-phos-
phorylated MAPK antibody using the ECL system. Anti-ACTB
antibody was utilized as an internal control.
Inhibition of gene expression by shRNAs
The lentiviral plasmids expressing shRNAs directed against
several distinct regions of Mapk14 (sc-29434) or Rela (sc-
29411) were purchased from Santa Cruz Biotechnology
together with control shRNA plasmids (sc-108060). Mouse
Axl-expressing J774 cells were transfected with each shRNA-
containing plasmid using Lipofectamine 2000 (Thermo Fisher
Scientiﬁc, 11668-019) according to the manufacturer’s instruc-
tions. After transfection, cells were selected with 4 mg/ml of
puromycin (Sigma, P7255). Inhibition of MAPK14 expression
and RELA expression were determined by immunoblotting
with appropriate antibodies.
Measurement of NLRP3 inﬂammasome activation
Murine macrophages were treated with ATP, IFNA receptor
blocking antibody, LPS, glibenclamide, and/or recombinant
GAS6 as indicated and the cells were tested for inﬂammasome
activation by immunoblotting and ELISA.
ELISAs
IL1B and IL18 secretion levels were quantiﬁed by sandwich
ELISAs using mouse IL1B (eBioscience, BMS6002) and IL18
ELISA kits (eBioscience, BMS618/3) according to the manufac-
turer’s instructions.
Animal studies
Axl deﬁcient (axl¡/¡) mice were kindly provided by Dr. Lemke
(Salk Institute, La Jolla, CA) and backcrossed into the C57BL/
6J strain for more than 9 generations. Atg7-ﬂoxed mice (Atg7ﬂ/
ﬂ, C57BL/6 background) were kindly provided by Dr. Komatsu
(Tokyo Metropolitan Institute of Medica Science, Tokyo,
Japan). Atg7ﬂ/ﬂ mice were crossed with B6.129P2-Lyz2tm1(cre)Ifo/
J mice (Jackson Laboratory, 004781) where Cre recombinase
expression is under the control of lysozyme M promoter to
generate Atg7 conditional knockout mice with myeloid lineage
cell-speciﬁc deletion of Atg7 (Atg7ﬂ/ﬂ CKO) and their wild-type
counterparts (Atg7ﬂ/ﬂ CTRL). More information about the gen-
eration of Atg7ﬂ/ﬂ CKO and Atg7ﬂ/ﬂ CTRL mice was previously
described.28,29 Animal models of acute liver injury were created
by injecting either LPS or CCl4 into mice.
48,49 To induce LPS-
challenged acute liver injury, mice were intraperitoneally
injected with 2.5 mg/g of PBS-dissolved LPS. Mice were sacri-
ﬁced at 3, 6, and 12 h after LPS injection and mRNA transcripts
of Gas6 from liver or spleen tissue of sacriﬁced mice were mon-
itored by qRT-PCR. In addition, Kupffer cells, sera, and several
tissues were harvested from mice sacriﬁced at 12 h after LPS
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injection to perform qRT-PCR analyses, western blot analyses,
histological analyses, immunohistochemistry, and to measure
serum GPT, GOT1, and cytokine secretions. For induction of
CCl4-mediated acute liver injury, mice were injected intraperi-
toneally with 2 ml/g of CCl4 mixed with corn oil at a ratio of
1:9. Mice were sacriﬁced at 1, 2, and 3 d after CCl4 injection,
mRNA transcripts of Gas6 from liver tissue of sacriﬁced mice
were monitored by qRT-PCR. Also, Kupffer cells, sera, and
liver were harvested from mice sacriﬁced at 1, 2, and 3 d after
CCl4 injection to perform qRT-PCR analyses, western blot
analyses, histological analyses, immunohistochemistry, and to
measure serum GPT, GOT1, and cytokine secretions. To evalu-
ate the effect of glibenclamide in acute liver injury model, mice
were injected with LPS and 1 mg/g of DMSO-dissolved gliben-
clamide or CCl4 and glibenclamide. Kupffer cells and sera from
mice were harvested to perform western blot analyses and to
measure cytokine secretions. All animals received proper care
in accordance with a protocol based on the National Institutes
of Health Guide for the Care and Use of Laboratory Animals
and approved by the Institutional Animal Care and Use Com-
mittee at Korea University and Chungnam National University
(protocol numbers: KUIACUC-2014-259 and CNUH-014-
A0007).
Histological analyses and immunochemistry
Tissues were ﬁxed with 10% neutral buffered formalin (Sigma,
HT5011) and embedded in parafﬁn. Sections measuring 5 mm
were cut using a Leica CM1800 cryostat (Leica Microsystems,
Wetzlar, Germany), air dried at room temperature, and stained
with hematoxylin and eosin (H&E). The severity of liver injury
and necroinﬂammatory activity were scored using H&E stained
sections according to standard methods as previously
described.50,51 The severity of liver injury observed in the tissue
sections was scored as follows: 0, minimal or no evidence of
injury; 1, mild injury consisting of cytoplasmic vacuolation and
focal nuclear pyknosis; 2, moderate to severe injury with exten-
sive nuclear pyknosis, cytoplasmic hypereosinophilia, and loss
of intercellular borders; and 3, severe necrosis with disintegra-
tion of the hepatic cords, hemorrhage, and neutrophil inﬁltra-
tion. Ten different areas (£ 100 ﬁelds) were examined for
necroinﬂammatory activity. The necroinﬂammatory activity
observed in the tissue sections was scored as follows: 0, no
affected area; 1, less than 2 areas; 2, between 2 and 4 areas; 3,
between 5 and 10 areas; 4, more than 10 areas with necroin-
ﬂammatory activity.
For detection of ﬁbrin deposition, livers were perfused
through a portal vein with PBS and liver specimens were rapidly
sampled, ﬁxed in 10% zinc ﬁxative (BD Biosciences, 550523),
and embedded in parafﬁn. Tissue sections were incubated over-
night with rabbit anti-mouse ﬁbrinogen antiserum (1:5,000) fol-
lowed by treatment with the rabbit Vectastain Elite ABC kit
(Vector Laboratories, PK-6100). Antigen-antibody complexes
were detected using a DAB Substrate Kit (Vector Laboratories,
SK-4100). Immunohistochemical analysis was performed with
an anti-ACTA2 antibody coupled with Alexa Fluor 488-conju-
gated anti-mouse IgG (green ﬂuorescence), an anti-ADGRE1/
F4/80 antibody coupled with Alexa Fluor 488-conjugated anti-
rat IgG (green ﬂuorescence), an anti-MAP1LC3B antibody
coupled with Alexa Fluor 594-conjugated anti-rabbit IgG (red
ﬂuorescence) and an anti-ATG5 antibody coupled with Alexa
Fluor 594-conjuated anti-rabbit IgG (red ﬂuorescence) using a
Bond Max autostainer according to the manufacturer’s protocol
(Leica Microsystems, Wetzlar, Germany).
Kupffer cell isolation
Kupffer cells were isolated from mice as described previously.32
Brieﬂy, the portal vein of anesthetized mice was cannulated, and
the liver was perfused at 7 mL/min for 10 min with Gey balanced
salt solution (Sigma, G9779) without Ca2C at 37C. Subse-
quently, perfusion with Gey balanced salt solution containing
1.5 mMCaCl2 and 0.5 mg/mL of collagenase type IV (Invitrogen,
17104019) was performed for 10 min. The digested liver was dis-
sected out thoroughly on a petri dish and then the supernatant
was ﬁltered. The nonparenchymal cell fraction containing
Kupffer cells was separated by 3 cycles of differential centrifuga-
tion (30 £ g for 3 min). The supernatant was collected and cen-
trifuged (400 £ g for 3 min) to obtain nonparenchymal cell
pellets. Isolated nonparenchymal cells were stained with PE-con-
jugated anti-ADGRE1/F4/80 antibody coupled with anti-PE
microbeads and then Kupffer cells were isolated using a magnetic
bead-associated cell sorting system (Miltenyi Biotec, Bergisch
Gladbach, Germany). The purity of Kupffer cells was more than
90%, as assessed by ﬂow cytometry analyses.
Measurement of plasma GPT and GOT1
Plasma GPT and GOT1 levels were measured by the standard
colorimetric method using Asan GPT and GOT1 kits (Asan
Pharmaceutical, AM101-K) according to the manufacturer’s
instructions.
Measurement of ROS
Measurement of mitochondrial superoxide was done using
MitoSOX Red Mitochondrial Superoxide Indicator according
to the manufacturer’s instructions. Brieﬂy, isolated mouse peri-
toneal macrophages were treated with LPS (100 ng/ml), ATP
(5 mM) and/or recombinant GAS6 (100 ng/ml) for 6 h. After
treatment, cells were incubated in Hank’s balanced salt solution
(Invitrogen, 14025-092) with 5 mM MitoSOX Red for 10 min
at 37C and washed with PBS. Then, cells were harvested and
assessed by ﬂow cytometry.
PYCARD pyroptosome detection
PYCARD pyroptosomes were detected as described previ-
ously.52 Brieﬂy, isolated mouse peritoneal macrophages were
treated with LPS (100 ng/ml), ATP (5 mM) and/or recombi-
nant GAS6 (100 ng/ml) for 6 h. After treatment, cells were har-
vested and resuspended in 0.5 ml of ice-cold buffer (20 mM
HEPES-KOH, pH 7.5, 150 mM KCl, 1% NP-40, 0.1 mM PMSF
and protease inhibitor cocktail), and lysed by shearing 10 times
using a 21-gauge needle. Then the cell lysates were centrifuged
at 6,000 £ g for 10 min at 4C, and the pellets were washed
with PBS. The pellets were resuspended in 0.5 ml of 4 mM DSS
in PBS and cross-linked in a shaking incubator for 30 min at
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37C, and then centrifuged at 6,000 £ g for 10 min. The cross-
linked pellets were resuspended in 30 ml SDS sample buffer,
separated by 12% SDS-polyacrylamide gel electrophoresis and
immunoblotted with anti-mouse PYCARD antibody.
Statistical analyses
Mean values were compared using a Student t test for indepen-
dent variables. Signiﬁcant differences as determined by P values
of less than 0.05 and 0.01 are indicated with asterisks () and
(), respectively, on each graph.
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